Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
again, I agree....this is a decades long battle....the real will be recognized!!!
agreed!
lol, love it!
well put!
agreed, thank you!
Going well, looking forward to it!
Volume preceeds price.....
Absolutely!!!!
And glad to be one of the Strong 35!!!!!
good read...not positive, but a good read nonetheless....
https://seekingalpha.com/article/4296484-weekly-cannabis-report-bad-news-just-stop
I continue to add....my view is more long term on this type of investment...
The street wants Supreme to address it's gross margin...but it has been reluctant to do so. They want to deal in high-end items and play in that cannabis space...which is fine, but the street expects a lower GP to correspond to the higher end products, and is reluctant to reward the sales forecast without a better understanding of where margins will be...imho! I continue to accumulate at these levels....'hoping" the margins will justify the products and subsequent sales, satisfying the street....let's face it, sales with no profit is not sustainable for the long term. I think investors just want to see the fruit...
Date: October 16, 2019
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in Phase I/II Clinical Trial for Type-A
Symbols: SEOVF, SVA
Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes
Findings further validate Cell Pouch and therapeutic cell performance in Type-1 diabetes
LONDON, ONTARIO -- October 16, 2019 -- InvestorsHub NewsWire -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinicalstage regenerative medicine company, is pleased to announce the detection of enduring levels of Cpeptide (measured up to 30 days and ongoing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its ongoing Phase I/II Cell Pouch(TM) US clinical study of type-1 diabetes.
The detection of fasting C-peptide in the bloodstream of our first patient, in addition to Sernova’s recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body’s varied need for insulin production. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch.
“Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing Cpeptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch,” said Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. “We look forward to reporting ongoing results in additional patients as the trial progresses.”
The entry criteria of Sernova’s clinical study require patients to be C-peptide negative upon enrolment. C-peptide measured in the bloodstream is a biomarker of insulin and is widely used as a measure of insulin production by islet cells. C-peptide is typically measured following overnight fasting (fasting Cpeptide) and during a glucose tolerance test (glucose-stimulated C-peptide). Together these measures provide an index of the patient’s ability to control blood glucose through their production of insulin.
With the goal of improved blood glucose control and stabilization of fluctuating blood sugar levels commonly experienced in people with type-1 diabetes, a normalizing response can also decrease the likelihood of life threatening hypoglycemic unaware events, a key efficacy measure in the Sernova trial.
Sernova’s clinical trial is continuing active recruitment and enrollment of study participants and further results will continue to be reported as the study progresses.
ABOUT SERNOVA’S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Importantly, patients enrolled in Sernova’s clinical trial are incapable of producing C-peptide prior to implantation of Sernova’s Cell Pouch and therapeutic cells.
Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939.
For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA’S CELL POUCH
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulinproducing cells in humans.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
very exciting!
NEW MEDIA - the new MYFLIX Venture into digital streaming(www.MyFlix.com), has over 30-studio and film library participants, collectively with over 10,000 feature films and television episodic hours of entertainment. This platform will have (literally) THOUSANDS of movies not available on any other streaming site. Less than ten years ago, NETFLIX was a mail order video rental business. NOW they are among the top movers and shakers in the entertainment industry DESPITE having a very limited selection of programming for viewers. We believe that MYFLIX could be a revolutionary new streaming destination - and a massive turning point for Hannover House.
STOCK REGISTRATION - HHSE is currently on the "OTC-Pinksheets" exchange. This status has impeded some large, institutional investors and hedge funds from buying into the stock. However, the pending Form 10 filing(including audits), will elevate the stock to the OTC:QB status as an initial step towards possible further up-listing. The OTC:QB status will open the door to significant new shareholders, which most professional traders and investors feel will dramatically improve the PPS and trading volume for HHSE.
NO STOCK ISSUANCES / NO DILUTION - HHSE has not issued any new shares in the past three years, and management has repeatedly stated that there are no plans to dilute shareholders through any deals now in motion or anticipated in the future.
PRESENTLY UNDER-VALUED PPS - Based on the Price-Earnings ratio for other publicly traded film / entertainment distributors, HHSE should be enjoying a 22X share price based on earnings. HHSE is on target to realize $1,250,000 in earnings for FYE 12-31-2018. This supports a share price of $.034 at present... and does not take into account the tremendous good-will and enthusiasm factor for the upcoming launch of MyFlix. Some highly respected stock analysts have communicated to HHSE management their prediction that the company's activities could support a share price of $.15 - which is more than ten-times current pricing. Even if their predictions are off by 75% - there is still an easily justifiable share price that is many times more than current trading levels.
TIMING-TIMING-TIMING - The launch of Myflix is a "second generation" site, in that the digital streaming technology and consumer acceptance have already been established. With that essential battle already won, MyFlix can concentrate on becoming "the better mousetrap" for digital entertainment. You combine this ideal market timing with the company's stock registration uplist, the presence of significant new shareholders post-registration, and new distribution pacts for the company's core film distribution activities (SONY / CINEDIGM), many feel that NOW is the ideal time to take a position in HHSE shares (while the HHSE Price Per Share is artificially low). Are these professional traders right? We will all know very soon!
HHSE makes no representation, guarantee or warranty that our share price will improve significantly as a result of these and other current activities. Every stock investment involves risks and factors outside of the control of issuers and management. But we proudly share with you the above information, projections and rationale' that professional traders have identified as the basis for why they believe that NOW is a great time to look at HHSE.
FORM 10 REGISTRATION activities are well into motion. HHSE managers believe that the fully reporting status (automatic on 60-days after filing), will positively impact the company's share price and volume.
MAJOR INSTITUTIONAL INVESTORS / FUNDS - HHSE managers have been working with three major investors / fund groups, one of which has already accumulated a position in HHSE. The other two are restricted from acquiring Pinksheet equities, but have confirmed with HHSE their intentions to acquire significant shares "post registration." HHSE managers believe that the successful recruitment of these major funds into HHSE will have a very significant and positive impact to the share price, volume and liquidity.
ELIMINATION OF BALANCE SHEET DEBTS - As a component of the Registration filing, HHSE managers have successfully negotiated substantial reductions in debts currently carried on the Balance Sheet (which have been achieved without any new share issuances). HHSE managers feel that this will improve the optics of the company's liquidity and credibility to outside financiers.
hannoverhousemovies.blogspot.com/2018/07/r-rated-version-of-blood-feast-l
HHSE's "THE RIOT ACT" is a $2-mm Production, completed for $468,000 (!!)
Greetings HHSE Friends & Followers - Last November, HHSE facilitated the production of "THE RIOT ACT" (shot on location in and around Van Buren, Arkansas), by combining financial resources of distribution presales and State of Arkansas rebates with a bank credit line.
But one of the most valuable contributions to the film was the outstanding support received from the Fort Smith and Van Buren convention & tourism bureaus - which helped in securing wagons, costumed extras, horses, and an unprecedented "total shut down" of downtown Van Buren for a week... all at little or no cost to the production. With 70+ dump trucks of dirt, the streets and sidewalks were restored to 1903 status, and with limited expense on art direction, the buildings of Van Buren were converted to the proper period. The value of the in-kind goods and services is well in excess of $1-mm, and really made a huge difference with the final look of the film.
As another cost-cutting (free) expense to the production - HHSE managers (and the Executive Producers of the film, Eric Parkinson and Fred Shefte), took a quick break from supervisory duties, and appeared in a bit cameo as the local newspaper photographers.
THE RIOT ACT will open this Fall - the release specifics are still being finalized... but it's likely to follow the "Lady Bird" model, with the initial weekend focused on New York and Los Angeles. A full-page ad in the April Cinemacon issue of BOX OFFICE MAGAZINE generated over 200 playdate offers from all major circuits and key art house / specialty cinemas across the country... so the film has a lot of theatrical options available.
absolutely!
The Accum/Dist technical-indicator is a visual representation of the Accumulation (Buying, "holding"), of a stock versus the Distribution (Selling, "releasing") of stock back into the market.
Anyone can see HHSE has been accumulated with an uptrend (up-sloping trend-line) over a WIDE RANGE of prices (that's important), across the ENTIRE 6yr+ history of the chart. What makes the ACCUMULATION over a price range important is that IT SHOWS HHSE having been BOUGHT at HIGHER PRICES TOO,... & the trend REMAINS to ACCUMULATE (BUY & HOLD) rather than distribute (Sell & liquidate).
NO STOCK ISSUANCES / NO DILUTION - HHSE has not issued any new shares in the past three years, and management has repeatedly stated that there are no plans to dilute shareholders through any deals now in motion or anticipated in the future.
PRESENTLY UNDER-VALUED PPS - Based on the Price-Earnings ratio for other publicly traded film / entertainment distributors, HHSE should be enjoying a 22X share price based on earnings. HHSE is on target to realize $1,250,000 in earnings for FYE 12-31-2018. This supports a share price of $.034 at present... and does not take into account the tremendous good-will and enthusiasm factor for the upcoming launch of MyFlix. Some highly respected stock analysts have communicated to HHSE management their prediction that the company's activities could support a share price of $.15 - which is more than ten-times current pricing. Even if their predictions are off by 75% - there is still an easily justifiable share price that is many times more than current trading levels.
TIMING-TIMING-TIMING - The launch of Myflix is a "second generation" site, in that the digital streaming technology and consumer acceptance have already been established. With that essential battle already won, MyFlix can concentrate on becoming "the better mousetrap" for digital entertainment. You combine this ideal market timing with the company's stock registration uplist, the presence of significant new shareholders post-registration, and new distribution pacts for the company's core film distribution activities (SONY / CINEDIGM), many feel that NOW is the ideal time to take a position in HHSE shares (while the HHSE Price Per Share is artificially low). Are these professional traders right? We will all know very soon
wow, up 100% today! Nice!
https://globenewswire.com/news-release/2018/05/29/1513100/0/en/Kenadyr-Mining-Arranges-Strategic-Investment-from-Zijin-Mining-Group-Subsidiary-Gold-Mountain-Asset-Management-Ltd.html
Paulson added to his stake this past quarter........
International Tower Hill Mines (NYSEMKT:THM), Newmark Group (NASDAQ:NMRK), and Aetna Inc. (NYSE:AET): These very small (less than ~1% of the portfolio each) stakes saw substantial increases this quarter.
Note: Paulson has a ~32% ownership stake in International Tower Hill Mines.
Revolutionary Digital Streaming Site, MyFlix, Warmly Embraced by World Media Partners at Cannes Market
http://www.digitaljournal.com/pr/3772172
CANNES, FRANCE / ACCESSWIRE / May 14, 2018 / After four years of development under the project name of VODWIZ, independent studio Hannover House, Inc. (OTC PINK: HHSE) has announced the formal branding and launch of a multifaceted digital streaming platform, website and OTT channel. The venture, announced today at the Cannes Film Festival, will be branded as MyFlix, and will feature literally thousands of feature films and episodic television programs from more than twenty major suppliers.
Originally conceived as a streaming home for independent films, the Myflix portal will also include titles from several major studios, along with educational programming and video games.
"We are very excited about the enthusiastic response from program suppliers here at Cannes," said Fred Shefte, President of Hannover House. "Over the last four years, we built a foundation of support from independent studios with large libraries of titles. But we have since added alternative titles and higher-end theatrical hits. The Myflix portal has the potential to become one of the premier destination streaming sites for all entertainment programming."
Myflix will launch to consumers in July with the portal initially focusing on feature films and television programming, viewable on a per-transaction basis. Shortly after the initial TVOD launch, a "subscription-based" model will be made available to consumers, with an all-you-want-to-watch option for a flat monthly fee. The next phase of the site's evolution will be the addition of an educational portal featuring a wide range of subjects at different grade levels. Interactive tests will enable parents to reward "viewing credits" to their children, which can be redeemed for access to feature films or video games. A third phase for Myflix is the addition of video games, both as single player and live, interactive multiplayer platforms.
"Myflix is a second-generation portal for digital streaming," said Eric Parkinson, C.E.O. of Hannover House. "We have thoroughly studied the market and trends, and feel that we have taken positive steps to better the consumer experience for transactional choices, subscription breadth-of-programming, educational opportunities and rewards-based parental controls over video game access and usage," he concluded.
Private investment capital for the creation and launch of Myflix has been secured under a structure in which Hannover House will manage the venture and earn a significant upside. Additional details on the financing structure will be disclosed in an OTC Markets disclosure filing.
Feature Films & Television Programs
LAUNCHING SUMMER 2018
The initial stage of the Myflix platform launches this summer with an impressive selection of quality independent feature films - along with an assortment of major studio hits and popular television programming. Consumers will have the option to see literally THOUSANDS of films and programs on either a "per-transaction" basis (pricing starting at $1.99 per feature), or an all-you-can-watch monthly subscription (starting at $8 per month).
Program suppliers receive detailed monthly statements and direct ACH payments from the Myflix platform host.
Video Games
In early Fall 2018, Myflix will add a portal for consumers to access VIDEO GAMES, including multi-player interactive games as well as self-contained, single-player experiences. Access to the Video Games portal can be restricted or limited by parents under the Myflix subscription plan - enabling them to create rewards points earned from the Educational portal as a key to accessing the video games portal.
Educational Programming
In late Fall 2018, Myflix is adding a third portal for access to a wide range of educational programming. From the basics of Science, Technology, Engineering and Mathematics - to foreign language, history, geography, political theory, arts, music and more - the Myflix educational portal will provide consumers and students with a one-stop source for knowledge enrichment. Parents can also create rewards points for their kids, based on the successful completion of educational programs and tests.
For More Information Contact:
ERIC PARKINSON / Eric@HannoverHouse.com / Eric@MyFlix.com / 818-481-5277
SOURCE: Hannover House, Inc.
Read more: http://www.digitaljournal.com/pr/3772172#ixzz5FTs9B121
agreed, I think with continued strength in gold this stock should get to $1.40-$1.70, IMO
totally agree, 1.25 price target here
Makes sense to me
I found it interesting that Getting Grace is the only movie on Box Office MOJO projected to do more today than yesterday.....
I also had a friend catch the movie yesterday in Columbia, SC.....loved it, said it was a must see!
Midnight Sun had just slightly higher average, but was in over 2,000 theaters, and banked $4.1 million.....bring on some more theaters, this is a $10+ million movie not counting video, on demand, or rental income, IMO!
Go HHSE!
Go Getting Grace!
Getting Grace $108,000 first weekend in 60 theaters, $1,795 avg